Institute for Health, Health Care Policy & Aging Research, Rutgers University, New Brunswick, NJ, USA.
School of Social Work, Rutgers University, New Brunswick, NJ, USA.
J Gen Intern Med. 2023 Jun;38(8):1862-1870. doi: 10.1007/s11606-022-07991-7. Epub 2023 Jan 6.
Prescription opioids were a major initial driver of the opioid crisis. States have attempted to reduce overprescribing by enacting policies that limit opioid prescriptions, but the impacts of such policies on new prescribing and subsequent transitions to long-term use are not fully understood.
To examine the association of implementation of a state prescribing limits policy with opioid prescribing and transitions to long-term opioid use.
Interrupted time series analyses assessing trends in new opioid prescriptions and long-term use before and after policy implementation.
A total of 130,591 New Jersey Medicaid enrollees ages 18-64 who received an initial opioid prescription from January 2014 to December 2019.
New Jersey's opioid prescribing limit policy implemented in March 2017.
Total new opioid prescriptions, percentage of new prescriptions with >5 days' supply, and transition to long-term opioid use, defined as having opioid supply on day 90 after the initial prescription.
Policy implementation was associated with a significant monthly increase in new opioid prescriptions of 0.86 per 10,000 enrollees, halving the pre-policy decline in the prescribing rate. Among new opioid prescriptions, the percentage with >5 days' supply decreased by about 1 percentage point (-0.76 percentage points, 95% CI -0.89, -0.62) following policy implementation. However, policy implementation was associated with a significant monthly increase in the rate of initial prescriptions with supply on day 90 (9.95 per 10,000 new prescriptions, 95% CI 4.80, 15.11) that reversed the downward pre-implementation trend.
The New Jersey policy was associated with a reduction in initial prescriptions with >5 days' supply, but not with an overall decline in new opioid prescriptions or in the rate at which initial prescriptions led to long-term use. Given their only modest benefits, policymakers and clinicians should carefully weigh potential unintended consequences of strict prescribing limits.
处方类阿片药物是阿片类药物危机的主要初始驱动因素。各州已尝试通过实施限制阿片类药物处方的政策来减少过度处方,但这些政策对新处方和随后向长期使用的转变的影响尚未完全了解。
研究实施州处方限制政策与阿片类药物处方和向长期阿片类药物使用转变的关联。
在政策实施前后,采用中断时间序列分析评估新阿片类药物处方和长期使用的趋势。
2014 年 1 月至 2019 年 12 月,130591 名新泽西州医疗补助计划的 18-64 岁接受初始阿片类药物处方的参保者。
新泽西州的阿片类药物处方限制政策于 2017 年 3 月实施。
新的阿片类药物处方总数、新处方中>5 天供应量的百分比,以及向长期阿片类药物使用的转变,定义为初始处方后第 90 天有阿片类药物供应。
政策实施与新的阿片类药物处方每月增加 0.86/10000 名参保者显著相关,使处方率在政策实施前的下降趋势减半。在新的阿片类药物处方中,>5 天供应量的百分比在政策实施后下降了约 1 个百分点(-0.76 个百分点,95%置信区间-0.89,-0.62)。然而,政策实施与初始处方第 90 天有供应的处方率每月显著增加(9.95/10000 新处方,95%置信区间 4.80,15.11)有关,这扭转了政策实施前的下降趋势。
新泽西州的政策与>5 天供应量的初始处方减少有关,但与新的阿片类药物处方总数或初始处方导致长期使用的比例没有总体下降有关。鉴于它们的益处有限,政策制定者和临床医生应仔细权衡严格处方限制的潜在意外后果。